Doctor Melly Susanti

Doctor Melly Susanti

Ministry of Health Surabaya Central General Hospital, Jawa Timur (Indonesia)

Member of:

Melly Susanti, MD is a cardiologist and interventional fellow at Korea University Guro Hospital, Seoul. Since starting her fellowship in February 2025, she has been training in complex coronary and peripheral interventions, with particular interests in chronic total occlusion (CTO) PCI, intravascular imaging (IVUS/OCT), and endovascular therapies. Before her fellowship, Dr. Susanti worked as a cardiologist at the Ministry of Health Hospital Surabaya, in collaboration with the National Cardiovascular Center Harapan Kita, Indonesia. She completed her cardiology residency at Universitas Airlangga and Dr. Soetomo General Hospital, Indonesia. She has contributed to research on endothelial function, cardiac amyloidosis, and cardiovascular pharmacotherapy, with several peer-reviewed publications. Outside of clinical practice, Dr. Susanti is dedicated to cardiovascular health education and actively creates content to raise public awareness about heart disease.

Presentations

Impact of Carvedilol versus Bisoprolol on long-term clinical outcomes in STEMI patients with mid-range LVEF

Event: ESC Congress 2025

Topic: Epidemiology, Prognosis, Outcome

Session: Novel pharmacological approaches following an acute coronary syndrome

Access

Impact of 2nd-generation versus 3rd-generation beta-blockers on long-term clinical outcomes in STEMI patients treated with drug-eluting stents

Event: ESC Congress 2025

Topic: Pharmacotherapy

Session: Chronic coronary syndromes: prognosis

Access

Impact of 2nd-generation versus 3rd-generation beta-blockers on long-term outcomes on long-term clinical outcomes in ST-elevation myocardial infarction patients with mid-range LVEF

Event: ESC Congress 2025

Topic: Epidemiology, Prognosis, Outcome

Session: Pharmacotherapy in coronary artery disease (1)

Access

Impact of Nebivolol versus Carvedilol on long-term outcomes on long-term clinical outcomes in ST-elevation myocardial infarction patients with mid-range left ventricular ejection fraction (40% to 49%)

Event: ESC Congress 2025

Topic: ST-Elevation Myocardial Infarction (STEMI)

Session: Pharmacotherapy in acute coronary syndromes (4)

Access

Impact of discharge beta-blocker on long-term clinical outcomes in ST-elevation myocardial infarction patients with diabetes mellitus treated with drug-eluting stents

Event: ESC Congress 2025

Topic: Percutaneous Coronary Intervention (PCI) and Surgery

Session: Diabetes and the heart (2)

Access

Association of dyslipidemia with coronary artery spasm as assessed by an intracoronary acethycholine provocation test

Event: ESC Congress 2025

Topic: Coronary Angiography

Session: A deep dive into coronary physiology

Access

Impact of 2nd-generation versus 3rd-generation beta-blocker prescription at discharge on long-term clinical outcomes in STEMI patients with preserved LVEF treated with drug-eluting stents

Event: ESC Congress 2025

Topic: Epidemiology, Prognosis, Outcome

Session: Expanding pharmacological and non-pharmacological options for coronary disease

Access

Long-term clinical outcomes in patients with coronary artery spasm according to first responsive dose of intracoronary acetylcholine

Event: ESC Congress 2025

Topic: Epidemiology, Prognosis, Outcome

Session: Atypical coronary syndromes

Access

Impact of beta-blocker prescription at discharge on long-term clinical outcomes in ST elevation myocardial infarction patients with preserved LVEF and successful drug-eluting stent implantation

Event: ESC Congress 2025

Topic: Beta-Blockers

Session: Beta-blockers: traditional drugs opening new avenues

Access

Impact of beta-blocker Nebivolol versus Carvedilol prescription at discharge on long-term clinical outcomes in STEMI patients with preserved LVEF treated with drug-eluting stents

Event: ESC Congress 2025

Topic: ST-Elevation Myocardial Infarction (STEMI)

Session: Pharmacotherapy in acute coronary syndromes (1)

Access

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources

Doctor Melly Susanti

Biography

Contributor content

Impact of Carvedilol versus Bisoprolol on long-term clinical outcomes in STEMI patients with mid-range LVEF

Impact of 2nd-generation versus 3rd-generation beta-blockers on long-term clinical outcomes in STEMI patients treated with drug-eluting stents

Impact of 2nd-generation versus 3rd-generation beta-blockers on long-term outcomes on long-term clinical outcomes in ST-elevation myocardial infarction patients with mid-range LVEF

Impact of Nebivolol versus Carvedilol on long-term outcomes on long-term clinical outcomes in ST-elevation myocardial infarction patients with mid-range left ventricular ejection fraction (40% to 49%)

Impact of discharge beta-blocker on long-term clinical outcomes in ST-elevation myocardial infarction patients with diabetes mellitus treated with drug-eluting stents

Association of dyslipidemia with coronary artery spasm as assessed by an intracoronary acethycholine provocation test

Impact of 2nd-generation versus 3rd-generation beta-blocker prescription at discharge on long-term clinical outcomes in STEMI patients with preserved LVEF treated with drug-eluting stents

Long-term clinical outcomes in patients with coronary artery spasm according to first responsive dose of intracoronary acetylcholine

Impact of beta-blocker prescription at discharge on long-term clinical outcomes in ST elevation myocardial infarction patients with preserved LVEF and successful drug-eluting stent implantation

Impact of beta-blocker Nebivolol versus Carvedilol prescription at discharge on long-term clinical outcomes in STEMI patients with preserved LVEF treated with drug-eluting stents

ESC 365 is supported by

Doctor Melly Susanti Follow

Biography

Contributor content

Impact of Carvedilol versus Bisoprolol on long-term clinical outcomes in STEMI patients with mid-range LVEF

Impact of 2nd-generation versus 3rd-generation beta-blockers on long-term clinical outcomes in STEMI patients treated with drug-eluting stents

Impact of 2nd-generation versus 3rd-generation beta-blockers on long-term outcomes on long-term clinical outcomes in ST-elevation myocardial infarction patients with mid-range LVEF

Impact of Nebivolol versus Carvedilol on long-term outcomes on long-term clinical outcomes in ST-elevation myocardial infarction patients with mid-range left ventricular ejection fraction (40% to 49%)

Impact of discharge beta-blocker on long-term clinical outcomes in ST-elevation myocardial infarction patients with diabetes mellitus treated with drug-eluting stents

Association of dyslipidemia with coronary artery spasm as assessed by an intracoronary acethycholine provocation test

Impact of 2nd-generation versus 3rd-generation beta-blocker prescription at discharge on long-term clinical outcomes in STEMI patients with preserved LVEF treated with drug-eluting stents

Long-term clinical outcomes in patients with coronary artery spasm according to first responsive dose of intracoronary acetylcholine

Impact of beta-blocker prescription at discharge on long-term clinical outcomes in ST elevation myocardial infarction patients with preserved LVEF and successful drug-eluting stent implantation

Impact of beta-blocker Nebivolol versus Carvedilol prescription at discharge on long-term clinical outcomes in STEMI patients with preserved LVEF treated with drug-eluting stents

ESC 365 is supported by

Doctor Melly Susanti